Navigation Links
EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
Date:9/4/2007

INKSTER, Mich., Sept. 4 /PRNewswire/ -- EaglePicher Corporation (EaglePicher) today announced that it has completed its previously announced transaction to sell EaglePicher Boron, LLC (EP Boron) to Ceradyne, Inc. (Nasdaq: CRDN).

EP Boron, located in Quapaw, Oklahoma, has produced enriched boron isotopes and products containing other stable isotopes for the nuclear, semiconductor and hazardous materials industries. Its products include isotope B11, an additive to semiconductor grade silicon, and isotope B10, a neutron absorber.

Ceradyne develops, manufactures, and markets advanced technical ceramic products and components for defense, industrial, automotive/diesel, and commercial applications.

"EP Boron is a great complement to Ceradyne's existing assets, and I am pleased that this will provide a solid growth opportunity for the people and customers of Boron," said David Treadwell, president and CEO of EaglePicher. "I would like to recognize and thank the hard-working employees at EP Boron who contributed to making this transaction a success."

EP Boron sales were approximately $23 million in the fiscal year ending November 30, 2006. It is anticipated that the management team at EP Boron will remain in place. Over the last 18 months EaglePicher has focused on operational excellence and technological innovation throughout its business portfolio. It has also identified strategic players who could grow a particular business. "Ceradyne is an excellent example of that effort," said Treadwell.

"I am very excited to announce the completion of this transaction," said David Reed, Ceradyne's President of North American Operations. "Boron fits perfectly with Ceradyne's long-term strategy, and I look f
'/>"/>

SOURCE EaglePicher Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. iGATE Completes Phase I Testing Of Meningitis Vaccine
3. Delhi Hospital Completes 100 Liver Transplants
4. Roche Completes Acquisition of BioVeris
5. Drug May Make Breathing Easier for Millions
6. Hundred million dollar gift for malaria institute
7. George Bush pledges 200 million dollars for AIDS relief
8. Over Six Million HIV Infected People In South Africa- Finds A Survey
9. Hope for 11 million children facing death from illnesses
10. The forgotten epidemic killing millions
11. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 The deadline to ... this Friday, June 21 at midnight ET. This ... and innovative people who’ve raised the bar on ... http://www.minonline.com/ima . , Any consumer and b2b ... is eligible to enter. Additionally, advertising agencies and ...
(Date:6/19/2013)... Lake City, UT (PRWEB) June 19, 2013 ... companies : , In July 2013, Orriant is ... their participation rates, and maintain compliance with regulations. ... allowing employees to receive wellness incentives if their ... has announced they have been compliant with these ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... international study led by researchers at The University of ... continues to show remarkable promise for the treatment of ... most recent interim findings of the 18-center Phase 2 ... Journal of Medicine . Previous interim findings were presented ... Hematology Annual Meeting and Exposition. , Unprecedented ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... alert in India's northeast asking authorities to take ... outbreak in Bangladesh and Myanmar, officials said ... Tripura government has made arrangements for free consultation ... sub-divisions, especially those along the bordering areas," Tripura's ...
... known as a poison that can kill, arsenic also can ... leukemia , a new study out Saturday found. ... we give (arsenic) earlier in the course of treatment," said ... in North Carolina, and the lead author of the research ...
... issue of JAMA, has identified novel genetic mutations linked ... these mutations are due to both independent mutational events ... to coincide with its presentation at the annual meeting ... ,According to background information in the article, gastric cancer ...
... CHICAGO, According to a University of Pittsburgh Medical Center ... American Society of Clinical Oncology (ASCO) in Chicago and ... patients treated for follicular lymphoma, a slow-growing type of ... ,Over 90 percent of study patients responded ...
... CEGE) today announced follow-up data from a Phase 2 ... was conducted by the Johns Hopkins Sidney Kimmel Cancer ... pancreatic cancer who received GVAX after surgical resection of ... overall survival for these patients was previously reported to ...
... receiving end, even if it is all subtle, as in ... to pin down is more dangerous to mental health ... immigrants living in Canada. ,"We found that the ... distress such as symptoms of depression and anxiety," said lead ...
Cached Medicine News:Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 3Health News:Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... ARBOR, Mich., Nov. 11, 2011 Adeona ... developer of innovative medicines for serious central nervous system ... estriol), will be utilized in a new Phase II ... cognitive dysfunction observed in female multiple sclerosis (MS) patients. ...
... 11, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Officer, will be presenting at the Lazard Capital Markets 8th ... New York City. Mr. Bentsur,s presentation is scheduled to take ... A live audio webcast of Mr. Bentsur,s presentation ...
Cached Medicine Technology:Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 2Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 3Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 4Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 5Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: